New products and services from ProUroCare, Touch of Life Technologies, and MDxHealth.
Minneapolis-The FDA recently granted clearance for the ProUroScan prostate mechanical imaging system. ProUroScan will allow men to receive high-resolution visual documentations as an aid for detecting prostate abnormalities that have previously been detected by digital rectal examination (DRE). Using a handheld pressure-sensing rectal probe and elasticity imaging technology, the system-along with a DRE finding-produces real-time prostate maps and color imaging so that results can be permanently stored in electronic records. The manufacturer, ProUroCare, plans to introduce the technology in 2012.
Injection simulator trains urologists on treating OAB with botulinum
Epigenetic test helps identify men who may forego biopsies for PCa
Irvine, CA-ConfirmMDx is an epigenetic assay that helps urologists distinguish patients who have a true-negative prostate biopsy from those at risk for occult cancer. By detecting an epigenetic field effect, or molecular "halo" associated with the cancerization process at the DNA level in cells, ConfirmMDx aids urologists in identifying PCa-free men from high-risk patients so they may forego unnecessary repeat biopsies, according to manufacturer MDxHealth.
For more information, visit http://www.mdxhealth.com/.
Smartphone application provides flashcards on urology topics
New York-The Urology Flashcards smartphone application has more than 1,500 flashcards on various urology topics ranging from basic urology and erectile dysfunction to radiology, infections, and infertility. Developed by urologists, the app constantly updates to include up-to-date information in the field. The app is compatible with iPhones 3GS, 4, and 4S; iPod touch generations 3 and 4; and iPad and is available for download from iTunes.